Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Procrit vs No Procrit in AML and High-Risk MDS
NCT00656448Phase 3Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2008
- Primary completion
- Jun 2013
- Modality
- Biologic, rProtein (Recombinant Protein)
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of epoetin alfa in anemia (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Median Number of Participant Transfusions Required During 12 Weeks of Treatment. Started Mar 2008; status: completed.
02
Drugs
epoetin alfa
03
Conditions
anemia
Beyond the preview
Go deeper on NCT00656448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00656448.